Westpac Banking Corp reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 14.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 243,344 shares of the medical research company’s stock after selling 42,266 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.9% of Westpac Banking Corp’s investment portfolio, making the stock its 14th biggest holding. Westpac Banking Corp owned approximately 0.06% of Thermo Fisher Scientific worth $42,456,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Proficio Capital Partners LLC raised its position in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 253 shares during the period. Chicago Partners Investment Group LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $108,000. Cribstone Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares in the last quarter. Sharkey Howes & Javer grew its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $113,000. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/09/westpac-banking-corp-has-42-46-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the sale, the vice president now directly owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the sale, the vice president now directly owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is owned by company insiders.

Several equities analysts recently commented on the stock. Jefferies Group LLC restated a “hold” rating and issued a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. Barclays PLC reissued an “overweight” rating and issued a $215.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price for the company in a report on Thursday, September 21st. Finally, Cowen and Company reissued an “outperform” rating and issued a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $202.21.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.21 on Monday. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The stock has a market cap of $75.37 billion, a price-to-earnings ratio of 33.66 and a beta of 1.05. The firm has a 50-day moving average price of $186.68 and a 200 day moving average price of $173.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.03 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.